Evaluation of medicinal products for the treatment of irritable bowel syndrome - Scientific guideline

This document addresses the European Union regulatory position in the main topics of clinical development of new medicinal products in the treatment of irritable bowel syndrome.

Keywords: Irritable bowel syndrome, Rome criteria, patient reported outcome (PRO), health related quality of life (HrQoL)

Current effective version

Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - Revision 1

AdoptedReference Number: CPMP/EWP/785/97 Rev. 1Summary:

This guideline intends to address the EU regulatory position in the main topics of clinical development of new medicinal products in the treatment of patients with Irritable Bowel Syndrome (IBS).

Document history

Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - Revision 1

AdoptedReference Number: CPMP/EWP/785/97 Rev. 1Summary:

This guideline intends to address the EU regulatory position in the main topics of clinical development of new medicinal products in the treatment of patients with Irritable Bowel Syndrome (IBS).

Overview of comments received on guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome (CPMP/EWP/785/97 Rev. 1)

Reference Number: EMA/CHMP/266108/2014Summary:

Overview of comments received on Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome' (CPMP/EWP/785/97 Rev. 1)

Draft guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - Revision 1

Draft: consultation closedConsultation dates: 19/07/2013 to 15/01/2014Reference Number: CPMP/EWP/785/97 Rev. 1Summary:

This guideline intends to address the European Union regulatory position in the main topics of clinical development of new medicinal products in the treatment of patients with irritable bowel syndrome.

Concept paper on the revision of the CHMP points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome

Draft: consultation closedConsultation dates: 08/06/2012 to 31/08/2012Reference Number: EMA/CHMP/172616/2012Summary:

The proposed guideline will replace 'points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome CPMP/EWP/785/97'. Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder in which abdominal discomfort or pain is associated with changes in bowel habits, stool consistency and other features of disordered defecation.

Points to consider on the evaluation of medicinal products for the treatment of Irritable Bowel Syndrome

AdoptedReference Number: CPMP/EWP/785/97Legal effective date: 01/09/2003